Cytosorbents Corp
CTSONasdaq
$0.36
↓ -2.5%Jul 17 close · end-of-day
Price
1Y↓ -65.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$22.6M
Enterprise Value
$34.7M
P/E
—
P/S
0.6
P/B
10.3
EV/EBITDA
—
PEG
—
FCF Yield
-45.4%
Dividend Yield
—
Revenue (TTM)
$37.2M
Net Income (TTM)
-$11.8M
Free Cash Flow (TTM)
-$10.2M
Gross Margin
71.0%
Operating Margin
-37.4%
Net Margin
-31.9%
ROE
-540.0%
ROIC
-76.6%
Debt / Equity
7.7
Net Cash
-$12.1M
Return 1Y
-63.6%
Company profile
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices. Its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.
- CEO
- Phillip P. Chan
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 220
- Headquarters
- New Jersey
- Website
- cytosorbents.com
Management & directors
- Chan Phillip P.Chief Executive Officer
- Mariani Peter JChief Financial Officer
- Capponi VincentPresident and COO
- Deliargyris EfthymiosChief Medical Officer
Roles derived from SEC Form 4 filings.
Earnings
CTSO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$8.9M↑ +1.6%
Diluted EPS-$0.08↑ +300.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $41.0M | $43.2M | $34.7M | $31.1M | $35.6M | $37.1M |
| Gross profit | $30.0M | $32.1M | $20.7M | $22.0M | $24.9M | $26.5M |
| Operating income | -$10.4M | -$22.7M | -$31.5M | -$31.9M | -$16.5M | -$14.7M |
| Net income | -$7.8M | -$24.6M | -$32.8M | -$29.2M | -$20.7M | -$8.2M |
| Diluted EPS | -$0.20 | -$0.57 | -$0.75 | -$0.65 | -$0.38 | -$0.13 |
| Operating cash flow | -$5.6M | -$14.0M | -$28.2M | -$21.7M | -$14.4M | -$12.4M |
| Free cash flow | -$6.3M | -$17.6M | -$34.3M | -$22.2M | -$14.7M | -$12.5M |
| Gross margin | 73.0% | 74.4% | 59.8% | 70.6% | 69.9% | 71.5% |
| Operating margin | -25.3% | -52.7% | -90.9% | -102.8% | -46.2% | -39.8% |
| Net margin | -19.1% | -56.9% | -94.6% | -94.1% | -58.2% | -22.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.8M | $8.6M | $9.2M | $8.7M | $9.6M | $9.5M | $9.2M | $8.9M |
| Gross profit | $6.5M | $5.3M | $6.3M | $6.2M | $6.8M | $6.7M | $6.8M | $6.1M |
| Operating income | -$3.6M | -$4.8M | -$3.4M | -$3.9M | -$3.6M | -$2.9M | -$4.4M | -$3.0M |
| Net income | -$4.3M | -$2.8M | -$7.6M | -$1.5M | $1.9M | -$3.2M | -$5.5M | -$5.1M |
| Diluted EPS | -$0.08 | -$0.05 | -$0.14 | -$0.02 | $0.03 | -$0.05 | -$0.09 | -$0.08 |
| Operating cash flow | -$4.8M | -$2.5M | -$2.3M | -$3.5M | -$1.5M | -$2.6M | -$4.8M | -$1.2M |
| Free cash flow | -$4.8M | -$2.6M | -$2.4M | -$3.5M | -$1.5M | -$2.6M | -$4.9M | -$1.2M |
| Gross margin | 73.5% | 61.0% | 68.4% | 71.1% | 70.9% | 70.3% | 73.7% | 69.2% |
| Operating margin | -40.4% | -56.1% | -37.1% | -44.6% | -37.6% | -30.2% | -47.5% | -34.3% |
| Net margin | -48.6% | -32.1% | -82.7% | -16.9% | 20.2% | -33.4% | -59.5% | -57.9% |
Company news
Jun 23, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-15 | MARIANI PETER J· Chief Financial Officer | Buy | 100,000 | $0.44 | $44,000.00 | filing |
| 2026-06-15 | Chan Phillip P.· Chief Executive Officer | Buy | 10,333 | $0.43 | $4,443.19 | filing |
| 2026-06-12 | Chan Phillip P.· Chief Executive Officer | Buy | 251,136 | $0.40 | $100,454.40 | filing |
| 2025-11-18 | Chan Phillip P.· Chief Executive Officer | Award | 100,000 | $0.64 | $64,000.00 | filing |
| 2025-08-08 | Chan Phillip P.· Chief Executive Officer | Award | 105,600 | $0.00 | $0.00 | filing |
| 2025-08-08 | MARIANI PETER J· Chief Financial Officer | Award | 71,500 | $0.00 | $0.00 | filing |
| 2025-08-08 | Capponi Vincent· President and COO | Award | 89,100 | $0.00 | $0.00 | filing |
| 2025-08-08 | Deliargyris Efthymios· Chief Medical Officer | Award | 70,000 | $0.00 | $0.00 | filing |
Latest 8 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.